Through the integrated analyses of three large datasets encompassing gene expression data on AML samples and healthy controls (i.e., TCGA versus GTEX, GSE15061, and Bloodspot) [16–18], we found that the expressions of PARP6 and PARP10 were simultaneously higher in AML cells than in normal cells, while the differential expression patterns of the other genes showed discrepancies across the three datasets, which indicated that targeting PARP6 and PARP10 might offer the more plausible option than targeting PARP1/2 in precision medicine. This evidence concerns the gene PARP1 and acute myeloid leukemia.